AstraZeneca PLC (NASDAQ:AZN - Free Report) - Equities research analysts at Zacks Research cut their Q1 2025 EPS estimates for AstraZeneca in a note issued to investors on Wednesday, April 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.06 for the quarter, down from their previous estimate of $1.08. The consensus estimate for AstraZeneca's current full-year earnings is $4.01 per share. Zacks Research also issued estimates for AstraZeneca's Q2 2025 earnings at $1.15 EPS, Q3 2025 earnings at $1.18 EPS, Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.65 EPS, Q1 2026 earnings at $1.23 EPS and FY2026 earnings at $5.24 EPS.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion for the quarter, compared to analyst estimates of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The company's quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the business earned $0.69 EPS.
AZN has been the topic of a number of other research reports. Morgan Stanley initiated coverage on AstraZeneca in a report on Tuesday, January 23rd. They issued an "overweight" rating on the stock. Jefferies Financial Group lowered AstraZeneca from a "buy" rating to a "hold" rating in a report on Wednesday, January 3rd. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a "hold" rating to a "sell" rating in a report on Thursday, February 8th. Finally, HSBC began coverage on shares of AstraZeneca in a research report on Monday, December 18th. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.00.
Read Our Latest Stock Analysis on AstraZeneca
AstraZeneca Stock Up 0.8 %
AZN stock traded up $0.53 during mid-day trading on Thursday, hitting $67.34. The stock had a trading volume of 7,453,464 shares, compared to its average volume of 6,233,873. AstraZeneca has a 1-year low of $60.47 and a 1-year high of $76.56. The company has a fifty day moving average of $65.69 and a 200 day moving average of $65.80. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $208.78 billion, a price-to-earnings ratio of 34.80, a PEG ratio of 1.23 and a beta of 0.50.
Hedge Funds Weigh In On AstraZeneca
Several large investors have recently bought and sold shares of the stock. Fairfield Bush & CO. bought a new stake in shares of AstraZeneca in the 2nd quarter worth approximately $25,000. ICA Group Wealth Management LLC bought a new stake in AstraZeneca in the 4th quarter valued at $26,000. Anchor Investment Management LLC bought a new position in shares of AstraZeneca during the 4th quarter worth about $26,000. Parkside Financial Bank & Trust boosted its position in shares of AstraZeneca by 4,875.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company's stock valued at $26,000 after acquiring an additional 390 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA acquired a new position in AstraZeneca in the fourth quarter worth about $27,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Increases Dividend
The firm also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were issued a dividend of $0.965 per share. The ex-dividend date was Thursday, February 22nd. This is a positive change from AstraZeneca's previous Semi-Annual dividend of $0.47. This represents a dividend yield of 2.3%. AstraZeneca's payout ratio is 100.52%.
About AstraZeneca
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
